R‑Zero Raises $15M, Democratizing Access to Biosafety Technologies in the COVID-19 Era and Beyond

November 13, 2020

R‑Zero, a biosafe­ty com­pa­ny ded­i­cat­ed to devel­op­ing the most effec­tive hos­pi­tal-grade tech­nolo­gies to reduce the spread of infec­tious dis­ease, today announced $15M in new cap­i­tal and remark­able busi­ness momen­tum, just three months after first intro­duc­ing its ger­mi­ci­dal UV device.


In today’s world, noth­ing is more impor­tant than the health and safe­ty of our fam­i­lies, fel­low employ­ees and front­line work­ers, but unfor­tu­nate­ly the cost of effec­tive dis­in­fec­tion pro­to­cols has been pro­hib­i­tive­ly expen­sive,” said Ira Ehren­preis, Man­ag­ing Part­ner at DBL Part­ners and R‑Zero board mem­ber. “Through inno­va­tion and cost reduc­tion, R‑Zero democ­ra­tizes access to safe­ty for busi­ness­es and com­mu­ni­ties alike. In much the same way as com­pa­nies in oth­er crit­i­cal indus­tries have expe­ri­enced expo­nen­tial growth by unlock­ing new tech­nolo­gies and attract­ing a new breed of entre­pre­neur­ial tal­ent, R‑Zero is sim­i­lar­ly poised to ben­e­fit from impact invest­ment dol­lars. The goal is to mod­ern­ize the dis­in­fec­tion space with its break­through tech­nol­o­gy, aimed at address­ing the crit­i­cal soci­etal issues around trust, appro­pri­ate health pro­to­cols, and the need for safer spaces.”

To learn more, please vis­it Ven​ture​Beat​.com.